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(MIR) has not been investigated in detail. We hypothesized that specific MIRs might be regulated di-
rectly in the endothelium thereby contributing to vascular leakage. METHODS SmallRNA sequencing of
endotoxemic murine pulmonary endothelial cells (ECs) was done to detect regulated vascular MIRs. In
vivo models: transgenic zebrafish (flk1:mCherry/l-fabp:eGFP-DPB), knockout/wildtype mouse (B6.Cg-
Mir155tm1.1Rsky/J); disease models: LPS 17.5 mg/kgBW and cecal ligation and puncture (CLP); in
vitro models: stimulated human umbilical vein EC (HUVECs), transendothelial electrical resistance. RE-
SULTS Endothelial MIR155 was identified as a promising candidate in endotoxemic murine pulmonary
ECs (25 × upregulation). Experimental overexpression in a transgenic zebrafish line and in HUVECs was
sufficient to induce spontaneous vascular leakage. To the contrary, genetic MIR155 reduction protects
against permeability both in vitro and in endotoxemia in vivo in MIR155 heterozygote knockout mice
thereby improving survival by 40%. A tight junction protein, Claudin-1, was down-regulated both in
endotoxemia and by experimental MIR155 overexpression. Translationally, MIR155 was detectable at
high levels in bronchoalveolar fluid of patients with ARDS compared to healthy human subjects. CON-
CLUSIONS We found that MIR155 is upregulated in the endothelium in mouse and men as part of
a systemic inflammatory response and might contribute to the pathophysiology of vascular leakage in
a Claudin-1-dependent manner. Future studies have to clarify whether MIR155 could be a potential
therapeutic target.
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Role of endothelial microRNA 155 
on capillary leakage in systemic inflammation
Valerie Etzrodt1† , Temitayo O. Idowu1†, Heiko Schenk1,9, Benjamin Seeliger2, Antje Prasse2, Kristina Thamm1, 
Thorben Pape1, Janina Müller-Deile3, Matijs van Meurs4, Thomas Thum5, Ankita Garg5, Robert Geffers6, 
Klaus Stahl7, Samir M. Parikh8, Hermann Haller1,9 and Sascha David1,10*
Abstract 
Background: Capillary leakage is a key contributor to the pathological host response to infections. The underlying 
mechanisms remain incompletely understood, and the role of microRNAs (MIR) has not been investigated in detail. 
We hypothesized that specific MIRs might be regulated directly in the endothelium thereby contributing to vascular 
leakage.
Methods: SmallRNA sequencing of endotoxemic murine pulmonary endothelial cells (ECs) was done to detect regu-
lated vascular MIRs. In vivo models: transgenic zebrafish (flk1:mCherry/l-fabp:eGFP-DPB), knockout/wildtype mouse 
(B6.Cg-Mir155tm1.1Rsky/J); disease models: LPS 17.5 mg/kgBW and cecal ligation and puncture (CLP); in vitro models: 
stimulated human umbilical vein EC (HUVECs), transendothelial electrical resistance.
Results: Endothelial MIR155 was identified as a promising candidate in endotoxemic murine pulmonary ECs 
(25 × upregulation). Experimental overexpression in a transgenic zebrafish line and in HUVECs was sufficient to induce 
spontaneous vascular leakage. To the contrary, genetic MIR155 reduction protects against permeability both in vitro 
and in endotoxemia in vivo in MIR155 heterozygote knockout mice thereby improving survival by 40%. A tight junc-
tion protein, Claudin-1, was down-regulated both in endotoxemia and by experimental MIR155 overexpression. Trans-
lationally, MIR155 was detectable at high levels in bronchoalveolar fluid of patients with ARDS compared to healthy 
human subjects.
Conclusions: We found that MIR155 is upregulated in the endothelium in mouse and men as part of a systemic 
inflammatory response and might contribute to the pathophysiology of vascular leakage in a Claudin-1-dependent 
manner. Future studies have to clarify whether MIR155 could be a potential therapeutic target.
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Background
Sepsis is defined as a life-threatening pathological host 
response to infection [1]. Key components of this host 
response are (1) a dysfunctional (often overwhelming) 
immune reaction, (2) intravascular coagulopathy and 
(3) global endothelial dysfunction all together leading to 
a microvascular stasis, organ hypo-perfusion and ulti-
mately fatal multi-organ failure. The mortality ranges 
between 32 and 56% [1, 2]. A deleterious vascular mal-
adaptation can occur in virtually all syndromes that are 
characterized by a systemic inflammatory response 
both in septic and aseptic conditions (e.g., pancreatitis, 
burns, post-cardiopulmonary bypass) [3]. The underlying 
molecular mechanisms have been investigated for some 
time but are still incompletely understood. The molecular 
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basis for maintenance of cell–cell contacts is the so-called 
adherens and tight junctions, transmembrane proteins 
that dynamically link adjacent cells to one another [4]. 
These junctions consist of a variety of proteins that are 
connected and form a robust scaffold with the intracellu-
lar actin cytoskeleton. Targeting one component of these 
complicated structures might have catastrophic effects 
on the stability of the whole complex. Some of these 
junctional proteins have been demonstrated to be altered 
in expression, structure and/or localization in systemic 
inflammation (e.g., VE-cadherin, catenins, Claudin-1 [5]).
MicroRNAs (MIR)—small non-coding RNAs that have 
the ability to simultaneously regulate a variety of pro-
teins—have not been investigated in detail in modulat-
ing the endothelial junctional apparatus thus controlling 
permeability [6]. In this context, one could hypothesize, 
that MIRs could trigger mechanisms that affect endothe-
lial barrier function by targeting both essential proteins 
of the junctional apparatus or of the cytoskeleton either 
in a beneficial or harmful nature.
We hypothesized that specific MIRs might be up-/
or down-regulated in systemic inflamed endothelium 
thereby contributing to the degradation of critical com-
ponents of endothelial junctions or cytoskeletal compo-
nents. To analyze this, we first performed an unbiased 
MIR analysis using a small RNA sequencing strategy 
from endotoxemic murine pulmonary endothelial cells 
and identified MIR155 as a potential candidate of inter-
est. We then analyzed endothelial MIR155 regulation in 
systemic inflammation in transgenic zebrafish, wildtype 
and knockout mice, human endothelial cells, septic 
human kidney biopsies, and in bronchoalveolar lavage 
fluid (BALf) and serum samples from ARDS patients.
Material and methods
We followed the ARRIVE guidelines (www.arriv eguid 
eline s.org) throughout the investigation whenever 
applicable.
Antibodies and reagents
All chemical and reagents, unless otherwise specified, 
were purchased from Sigma-Aldrich. Antibodies against 
Claudin-1, ZO-1, GAPDH and Alexa Fluor 546 Phal-
loidin, 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich, St.Louis, MO) and Aqua-Poly/Mount were used.
miRNA analysis using smallRNA‑Seq
RNA sequencing library was generated from 0.1 to 1 µg 
of total RNA using TruSeq® Small RNA Library Prep Kits 
v2 (Illumina) according to manufacturer’s protocols. The 
libraries were sequenced on Illumina HiSeq2500 using 
TruSeq SBS Kit v3-HS (50 cycles, single ended run) with 
an average of 10 × 106 reads per RNA sample. FASTQ 
files were trimmed with fastq-mcf (ea-utils, https ://expre 
ssion analy sis.githu b.io/ea-utils /) removing Illumina RNA 
adapter sequences (TGG AAT TCT CGG GTG CCA AGG) 
and nucleotides with phred scores below 20. [7–10]
Cell culture studies
Human umbilical vein endothelial cells (HUVECs) were 
isolated from human umbilical veins (donor approval, 
Hannover Medical School Nr. 1303-2012). Specific 
miRCURY LNA miRNA mimic (No. 339173) (Qiagen, 
Hilden, Germany) was used to overexpress the micro-
RNA 155. To inhibit the microRNA 155, the miRCURY 
LNA miRNA Inhibitor 5  nM was used (No. 339121) 
(Qiagen, Hilden, Germany).
Mouse studies
All mouse experiments were approved by the local 
authorities at Hannover Medical School and conducted 
in accordance with institutional and governmental guide-
lines (LAVES Lower Saxony, Ref. No. 18/2817). Male 
B6.Cg-Mir155tm1.1Rsky/J were used as MIR155 knock-
out mouse. The mice, 10–12  weeks of age, were either 
injected intraperitoneally (i.p.) with 17.5  mg/kg body-
weight lipopolysaccharide (LPS) or a cecal ligature punc-
ture (CLP) as described elsewhere [11] was conducted. 
Briefly, the LPS originated from Escherichia coli, sero-
type O111:B4 (Sigma-Aldrich, St. Louis, MO) dissolved 
in 10 mL/kg sterile NaCl. The injected mice were moni-
tored and scored according to Additional file 1: Table S4. 
After 16  h, they were killed and organs harvested. For 
the performance of the CLP experiment, the mice were 
anaesthetized with isoflurane (1–2% in medical air) and 
a midline laparotomy was placed by a single-blinded 
operator. The anti-mesenteric border was ligated, and 
through one single 20G needle puncture 1  mm of stool 
was extracted. As a sham surgery, laparotomy with cecal 
mobilization was performed. Followed by the two-lay-
ering closure, mice were given 200 µL of NaCl fluids s.c. 
and for analgesia once 10  mg/mL Butorphanol (Zoetis 
Manufacturing & Research, Spain). Until the organ har-
vest 24  h later, the mice were monitored and scored by 
a single-blinded investigator. The Evans Blue permeabil-
ity assay (EB) was conducted as described [11]. In brief, 
the mice were injected with the 100 µL of 2% wt/vol EB 
in the tail vein 12 h after LPS injection. For lung cuffing, 
mice were challenged with LPS (17.5  mg/kg BW) and 
killed 16  h later and organs were harvested. After the 
staining process, a lung cuffing score and a percentage of 
cuffing (yes / no) were raised by a single-blinded person 
(see Additional file 1: figure S1 and table S2). For Kaplan–
Meier survival studies, both models, i.e., LPS and CLP 
were used. All experiments were performed and analyzed 
by a blinded investigator.
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Western blot analysis
The Western Blot Analysis was conducted as in [12] 
described using the SuperSignal™ West Pico Chemilu-
minescent Substrate (Life Technologies) and Versa Doc 
Imaging System Model 3000 (BioRad, Hercules, CA) was 
used to visualize the bands.
Fluorescent immunocyto‑/histochemistry
HUVECs were grown to confluency on Collagen (Sigma-
Aldrich, St.Louis, MO) covered coverslips. Antibodies 
and reagents were used as described above.
Paraffin slices were deparaffined and blocked with 
10% donkey serum (Jackson Immuno Research Inc., 
West Grove, PA). GR-1 was used as primary antibody 
and pictured with the secondary antibody (goat anti-
rat IgG (Alexa flour 555)) (Invitrogen, CA). To evaluate 
the amount of lung cuffing through scores, mice lungs 
were stained with Periodic Acid Schiff (PAS) Staining 
and scored according to Additional file 1: Table S2. The 
images were taken with the Leica DMI 6000B microscope 
under the same gain and offset conditions.
(Micro) RNA isolation and quantitative (q) PCR
For the isolation, the miRNeasy Mini Kit was used (Qia-
gen, Hilden, Germany) to extract both miRNA and RNA 
from HUVECs and organ tissue followed by Prime Script 
RT Reagent Kit (TaKaRa Bio Europe SAS, St Germain-
en-Laye, France) after the manufacturer’s instructions.
Immunoprecipitation of MIR155
HUVECs were plated at 1.8 × 105 cells/well in 6 well-
plate overnight and transfected with 200 pM biotinylated 
control miRNA mimics or 5′-Biotinylated MIR-155 mim-
ics (No. 339178) (Qiagen, Hilden, Germany) using HiPer-
fect (Qiagen, Hilden, Germany) in accordance with the 
manufacturer’s instructions. After 48  h of transfection, 
cells were harvested in 700 µL lysis buffer supplemented 
with Protease Inhibitor Cocktail (Roche, South San Fran-
cisco, CA) and RNaseOUT (Invitrogen) and incubated on 
ice for 20 min. Lysates were centrifuged at 10,000 × g for 
15 min at 4 °C after which 50 µl of the cytoplasmic lysate 
(input) was transferred into a new tube for RNA extrac-
tion. The remaining supernatant was incubated with 
activated Streptavidin-Dynabeads (Dynabeads M-280 
Streptavidin, Invitrogen) for 4  h at 4  °C. After several 
washing steps and centrifugation, the supernatant was 
taken for RNA extraction. RNA was subjected to qPCR 
using Claudin-1 specific primers. The analysis was done 
as follows: MIRNA pull-down/control pull-down (‘A’), 
miRNA input/control input (‘B’); fold enrichment = A/B.
Zebrafish studies
Female Tg(flk1:mCherry) zebrafish were mated with male 
Tg(l-fabp:eGFP-DPB) to generate Tg(flk1:mCherry/l-
fabp:eGFP-DPB) zebrafish offspring. Eggs were micro-
injected with a MIR155 mimic or a scrambled MIR 
(mirVana, life technologies) at the one to four cell stage 
at a concentration of 25 μM [13]. At 96 h post-fertiliza-
tion, the vascular integrity of the transgenic larvae based 
on flk1 expression in ECs was determined. In parallel, the 
plasma protein loss of eGFP-DBP was analyzed by meas-
urement of fluorescence intensity in the retinal vessel 
plexus [13]. The zebrafish animal studies were performed 
according to the National Institutes of Health Guideline 
for the Care and Use of Laboratory Animals. The Mount 
Desert Island Biological Laboratory (Bar Harbor, ME) 
animal care committee approved the animal protocol 
(IACUC protocol #1703). The analysis was performed 
using ImageJ (Version 1.60, National Institutes of Health, 
Bethesda, MD) and reported in arbitrary units.
Transendothelial electrical resistance (TER)
TER was measured using an electric cell-substrate 
impedance sensing system (ECIS) (Applied BioPhys-
ics Inc.). The continuous values were pooled at discrete 
time points and plotted versus time. Each conditions’ end 
point resistance was divided by its starting resistance to 
give the normalized TER [14].
Human kidney biopsies
Kidney biopsies were obtained directly post-mortem 
from patients aged 18  years or older, who died of sep-
sis. Kidneys from patients diagnosed with kidney cancer 
who underwent a total nephrectomy, served as controls 
as described in Aslan et  al. Crit. Care. (2014) [15]. The 
postmortem biopsies were waived by the Medical Ethical 
Committee of the UMCG, Groningen, The Netherlands 
(METc 2011/372) [15].
Expression of MIR155 in human septic serum 
and bronchoalveolar lavage fluid (BALf) of patients 
with ARDS
MIR155 expression was measured in serum and BALf 
samples collected within 24 h of disease onset in patients 
with ARDS (n = 16), with clinical details provided in 
Table  1 and in healthy controls (n = 5). The collection 
of the BALf and serum samples was approved accord-
ing to the ethics committee of Hannover Medical School 
(MHH, EK 8146_BO_K_2018). Total RNA was isolated 
from human BALf and serum samples using miRNeasy 
Serum/Plasma Advanced Kit (Qiagen, Cat. No. 217204) 
following manufacturer’s instructions. For the BALf anal-
ysis, we established a novel method base on the above 
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kit used for the serum. Cel_MIR-39 miRNA mimic (Qia-
gen, Cat. No. 219610) at a concentration of 1.6 × 108 
copies/µL was used as a spike-in miRNA control. The 
reverse transcription for miRNAs was done with equal 
volume of starting total RNA for each sample and spe-
cific TaqMan probes (Applied Biosystems; for MIR-155: 
Assay ID 002623 and for Cel_MIR-39: Assay ID 000200) 
using TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems, Cat. No. 4366597) as per the man-
ufacturer’s guidelines. ViiA7 system (Applied Biosys-
tems) was used to perform miRNAs’ quantification PCR 
(qPCR) with MIR-155 or Cel_MIR-39 specific TaqMan 
assays (Applied Biosystems) and Absolute Blue qPCR 
Mix (Abgene, Cat. No. AB-4136/B). The collection of the 
BALf and serum samples was approved according to the 
ethics committee of Hannover Medical School (MHH, 
EK 8146_BO_K_2018).
Statistical analysis
Statistical significance was evaluated using Mann–Whit-
ney test or one-way ANOVA unless otherwise noted. All 
experimental results are presented as mean ± SD, and 
a two-tailed p value of less than 0.05 was considered to 
indicate statistical significance. GraphPad Prism 6.0 (La 
Jolla, CA).
Results
Identification of MIRs that are regulated 
in the endothelium in systemic inflammation
Mice were challenged intraperitoneally with a high dos-
age of LPS (17.5  mg/kg bodyweight, n = 3) or vehicle 
(n = 3) to induce a systemic inflammatory response that 
regularly leads to severe pulmonary capillary leakage. 
Mice were killed after 24  h, and lungs were harvested 
for endothelial cell (EC) separation with a magnetic 
CD146 antibody strategy followed by isolation of MIRs. 
SmallRNA sequencing was performed together with the 
Helmholtz Institute (Brunswick, Germany). A heatmap 
of regulated MIRs of the 6 included animals is shown 
in Fig.  1a and Additional file  1: Table  S1. In summary, 
out of 318 investigated MIRs, 5 were down- and 31 up-
regulated (Fig.  1b and Additional file  1: Table  S2). Of 
note, MIR155—that had not been studied in the septic 
endothelium so far—showed the strongest signal in our 
analysis and was therefore followed-up on in the next 
experiments.
To confirm these earlier findings of the smallRNA seq, 
MIR155 was first quantified by RT-PCR from whole 
lung lysates in endotoxemic and control mice at differ-
ent time-points. Already after 4  h, we found a 6 × fold 
increase in the LPS-treated mice (Fig. 1c, p < 0.01). Given 
that MIR155 is also expressed by other cells types (e.g., 
epithelial and immune cells), we selected specifically 
 CD146+ pulmonary ECs, which showed an even larger 
upregulation (i.e., 8 × fold MIR155 increase, Fig.  1d, 
p < 0.01). To confirm these results in a cellular context 
and to set a system for further mechanistic in vitro stud-
ies, confluent HUVEC monolayers were stimulated with 
50  ng/mL TNFα (a key cytokine of systemic inflam-
mation) and harvested in a time-dependent fashion. 
Indeed, TNFα challenge of ECs was sufficient to induce 
a significant upregulation of the MIR155 already after 2 h 
(p < 0.01) with a maximum response exceeding 15 × fold 
after 24 h (p < 0.001, Fig. 1e).
Table 1 Clinical features of  acute respiratory distress 
syndrome (ARDS) patients
ARDS acute respiratory distress syndrome, CRP C-reactive protein, IQR 
interquartile range, paO2 arterial partial pressure of oxygen, PEEP positive end 
expiratory pressure, SOFA score sequential organ failure assessment score. 
MIR155 expression in relation to cel-MIR39 was lowest in healthy controls 
(1.03 ± 0.12) versus ARDS patients (12.23 ± 3.0)
Characteristic All (n = 16)
Age (y), median (IQR) 52 (43–66)
Male (%) 12 (75)
Body mass index (kg/m2), median (IQR) 27.7 (24.4–33.3)
Septic shock (%) 9 (56)
Pneumogenic focus (%) 7 (78)
Primary ARDS (%) 14 (88)
Diagnosis
Pneumonia due to 14 (88)
 Influenza A 4 (29)
 Streptococcus pneumononiae 4 (29)
 Legionella pneumophilia 1 (7)
 Staphylococcus aureus with septicaemia 1 (7)
 Unidentified pathogen 4 (29)
Pancreatitis with sepsis and secondary ARDS 1 (6)
Septic shock of unknown focus with secondary ARDS 1 (6)
Laboratory at time of sampling
CRP (mg/L), median (IQR) 252 (134–305)
Procalcitonin (ng/L), median (IQR) 7.7 (1.4–29.1)
Leukocytes (gpt/L), median (IQR) 8.2 (4.8–19.1)
Lactate (mmol/L), median (IQR) 1.6 (1.2–3.2)
paO2 /  FiO2 (mmHg), median (IQR) 109 (77–132)
SOFA score at day of sampling (IQR) 11.5 (8.5–13.0)
Treatment modalities at time of sampling
Invasive ventilation 16 (100)
PEEP (mbar), median (IQR) 14 (12–15)
Pmax (mbar), median (IQR) 26 (23–28)
Extracorporeal membrane oxygenation (%) 7 (44)
Renal replacement therapy (%) 10 (63)
Vasopressor use (%) 13 (81)
Noradrenaline dose (µg/kg/min), median (IQR) 0.085 (0.02–0.35)
28-day ICU-mortality (%) 5 (31)
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Functional consequences of MIR155 overexpression 
and inhibition in vivo
Given the lack of knowledge on the functional role of 
MIR155 in the endothelium, we investigated it in a 
transgenic Tg(flk1:mCherry)/Tg(l-fabp:eGFP-DBP) 
zebrafish line. This zebrafish model allowed us (1) to 
rapidly overexpress MIR155 by microinjection of a 
MIR155 mimic and (2) to analyze vascular phenotypes. 
Simplified, this transgenic fish expresses a red cherry 
protein in the vasculature and has an enhanced green 
fluorescent protein bound to Vitamin D binding pro-
tein (eGFP-DBP) (corresponds to the intravascular 
compartment, i.e., the plasma). Both loss of GFP inten-
sity in the retinal vessels and the development of peri-
cardial effusion can be used as a surrogate of vascular 
leak [13, 16]. Indeed, overexpression of MIR155 led to 
a visually detectable loss of GFP in the red vascular tree 
and fluid accumulation in the pericardium (Fig. 2a–c). 
Visualization and quantification of the retinal GFP 
expression showed a decrease in fluorescence intensity 
(p < 0.0001) supporting the hypothesis that experimen-
tal overexpression of MIR155 is sufficient to induce 
vascular permeability (even in the absence of systemic 
inflammation) (Fig. 2d–f ).
Fig. 1 Unbiased MIR screening and confirmation in the endothelium of mice with a systemic inflammatory response. Mice were either given LPS 
(17.5 mg/kg BW i.p.) or vehicle (0.9% NaCl) and killed after 24 h or at indicated time-points. a A smallRNA sequencing was conducted using isolated 
CD146 + pulmonary endothelial cells (ECs) from endotoxemic compared to healthy mice. Shown is a heat map that highlights the gene distribution 
with the arrow pointing to the upregulation of MIR155. b Volcano plot showing a log scaled distribution of 318 analyzed endothelial MIRs. 5 MIRs 
were down- and 31 upregulated; MIR155 (arrow) showed the strongest upregulation (c). Bar graphs showing normalized MIR155 expression in 
lung lysates via RT-PCR after 4, 12 and 24 h compared to control (CTR) (CTR: n = 8; LPS: n = 4–5). d Bar graphs showing normalized MIR155/Rnu6b 
expression in CD146 + pulmonary ECs (n = 5). e In vitro confirmation of time-dependent MIR155 upregulation in human umbilical endothelial cells 
(HUVEC) (n = 4–6) after stimulation with the proinflammatory cytokine TNFa (50 ng/mL) compared to vehicle (CTR); Bar graphs show mean ± SD of 
normalized MIR155 with a maximum of 15 × fold increase at 24 h. (c–e, all **p < 0.01)
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To assess the role of the MIR155 in mammals, knock-
out mice and littermate wildtypes were challenged with 
LPS or vehicle and permeability was assessed in vivo by 
the Evans Blue (EB) method. Septic wildtypes showed 
a 2.2 × fold increase in lung EB extravasation quanti-
fied by spectroscopic analysis of the grounded tissue. 
Interestingly, homozygote knockouts  (MIR155−/−) 
were not protected, but the heterozygote MIR155 
mice  (MIR155+/−) showed barrier properties that 
were indistinguishable from healthy controls (Fig.  3a). 
Bronchiolar cuffing is a histological method to visual-
ize pulmonary edema (Additional file 1: Fig. S1). Again, 
septic wildtype mice showed a severe cuffing pheno-
type (Fig. 3b, second panel) that was less severe in the 
heterozygote context (third panel) but not different in 
the  MIR155−/− mice (fourth panel). This finding was 
semi-quantified by a blinded investigator both with 
regard to the percentage of cuffing positive bronchi 
(Fig.  3c) and the severity of cuffing (Fig.  3d). In addi-
tion to these observations with regards to permeabil-
ity, we found additional evidence that the endothelial 
inflammatory response might be positively influenced 
if MIR155 is experimentally reduced (Additional file 1: 
Fig. S2). Together these findings support that MIR155 
upregulation in systemic inflammation might be an 
injurious contributor to vascular leakage across differ-
ent species.
Functional consequences of MIR155 overexpression 
and inhibition in vitro
In vitro, naïve or MIR155 modulated HUVECs were chal-
lenged with thrombin (a mediator of systemic inflam-
mation and an established inductor of EC permeability 
in vitro) to recapitulate the above described in vivo find-
ings. Thrombin stimulation primed the formation of 
F-actin polymerization and gap formation between adja-
cent ECs leading to an increase in permeability (white 
arrows) (Fig.  4a, lower left). ECs that have been chal-
lenged with a MIR mimetic (w/o thrombin) partly phe-
nocopied these permeability patterns (Fig.  4a, upper 
right). Interestingly, from a therapeutic point of view, 
ECs that have been co-stimulated with thrombin + anti-
MIR155 peptide were protected from the development of 
the before described endothelial morphological changes 
(Fig.  4a, lower middle panel). To reliably quantify these 
qualitative changes in morphology, we measured TER in 
real-time with Electric Cell-substrate Impedance Sens-
ing (ECIS). MIR155 overexpression was not sufficient 
Fig. 2 Functional consequences of MIR155 overexpression and inhibition in zebrafish. a–f Transgenic zebrafish larvae (Tg(flk1:mCherry)/Tg(I-fabp:eGF
P-DBP) were used to assess the role of MIR155 in vivo. Uninjected larvae (n = 26), scrambled MIR injected (25 µM, n = 16) and MIR155 injected larvae 
(25 µM, n = 26) were analyzed at 96 h post-fertilization. a Phenotype analysis shows the eGFP-DBP fusion protein (green) predominantly within the 
mcherry-flk1 positive vasculature (red) in the uninjected larva. b Equivalent eGFP-DBP expression is being detected in the scrambled MIR injection 
group. c MIR155 overexpression leads to loss of eGFP-DBP (green) from the mcherry-flk1 positive vasculature (#) (red) and shows accumulation 
in the pericardium and yolk sac (*). d To quantify protein leakage, the eGFP-DBP content was measured by detection of eGFP-DBP in the retinal 
vasculature in scrambled and in e the MIR155 injected fish. In the retinal vasculature of the MIR155 zebrafish, the fluorescence is diminished as 
eGFP-DBP is not detectable (arrow). f Box and whisker plots showing a quantification of protein leakage that was performed by measurement of 
the maximum fluorescence intensity of eGFP-DBP in the retinal vasculature indicating a significant loss in the MIR155 injected fish (***p < 0.0001)
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to induce leak in this assay by itself, but MIR155 over-
expression critically interfered with the usual recovery 
after stimulation with thrombin (Fig.  4b). More impor-
tant from a translational aspect, inhibition of MIR155 
(anti-MIR155) was sufficient to reduce the deleterious 
effect of thrombin in this highly sensitive assay (Fig. 4c, 
p < 0.05). Together these findings support our hypothesis 
that upregulation of MIR155 in the septic endothelium is 
indeed injurious and that its inhibition might represent a 
therapeutic target.
Identification of MIR155 target candidates
Using an in silico analysis tool (http://www.targe tscan 
.org), we identified 556 potential transcripts with pre-
served sites among various species that might be influ-
enced by MIR155. Given the permeability phenotype in 
our in vivo and in vitro models, we specifically looked at 
proteins involved in the junctional apparatus. The anal-
ysis predicted that Claudin-1 could be a possible target 
that additionally showed conserved binding sites among 
different species (e.g., human, cow, rat, mouse, dog). First, 
we checked if Claudin-1 expression is indeed altered 
in LPS-treated mice and found a significant reduction 
in their lungs (Fig.  4d). Experimental up-regulation of 
MIR155 in ECs in vitro to a similar extent that we earlier 
detected in systemic inflamed mice (Additional file  1: 
Fig. S3) induced a significant downregulation of Clau-
din-1 on mRNA and protein levels (Fig. 4e, f ). Using an 
immunoprecipitation strategy from ECs stimulated with 
an MIR155 mimetic, we could confirm the physical bind-
ing of MIR155 with claudin-1 (Fig. 4g). However, inhibi-
tion of MIR155 was not sufficient to increase Claudin-1 
expression spontaneously (data not shown).
Effect of MIR155 depletion on clinical outcomes in murine 
sepsis
Next, we tested if the previously observed attenua-
tion of permeability in the MIR155 heterozygote mice 
might be sufficient to protect from organ dysfunction 
and death. Analysis of functional organ parameters from 
serum samples 24 h after LPS administration in all geno-
types showed trends towards improved organ function 
and survival in a 100% lethal model (Additional file  1: 
Table  S3 and Fig. S3.) in the heterozygous  MIR155+/− 
mice (median survival  MIR155+/− 25.5  h vs  MIR155+/+ 
36 h). The 100% lethality of our endotoxemia model com-
bined with increasing doubts regarding the clinical rele-
vance of this model in the sepsis community [17] inspired 
us to test outcome in a clinically more meaningful pol-
ymicrobial sepsis model, i.e., CLP. Upon CLP surgery, 
Fig. 3 Functional consequences of MIR155 overexpression and inhibition in mice. B6.Cg-Mir155tm1.1Rsky/J knockout mice and wildtype litters 
were challenged with LPS (17.5 mg/kg BW i.p.) or vehicle (0.9% NaCl) and killed after 16 h. a Bar graphs showing Evans blue extravasation in the 
lung of healthy control mice (CTR, n = 5) and LPS challenged B6.Cg-Mir155tm1.1Rsky/J knockout mice (n = 3–12) b–d Perivascular fluid cuffs (lung 
cuffing) were evaluated. b PAS staining indicating the bronchi (b), its corresponding arterial vasa vasorum (a) and cuffing (black arrows). c Bar graph 
showing the percentage of lung cuffing. Indicating a significant difference between the LPS challenged  MIR155+/+ (n = 8) and  MIR155+/− group 
(n = 9; p = 0.001). d Bar graph showing the lung cuffing severity score of single bronchi (n = 41–263 arteriolae per group) from a total of 27 mice. 
(*p < 0.05, **p < 0.01, ***p < 0.0001)
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Fig. 4 Functional effects of MIR155 on permeability and target candidates. a Control, Anti-MIR155 and  MIR155high human umbilical vein endothelial 
cells (HUVECs) were challenged with thrombin or vehicle following staining with a tight-junction protein (ZO-1, green), the cytoskeleton (F-actin, 
red) and DAPI (blue). Thrombin challenged ECs showed visible gap formation between adjacent cells (white arrows). Blockade of MIR155 had 
visually lesser gap formations upon thrombin stimulation (lower middle panel). Whereas the  MIR155high transfected HUVECs showed mild 
spontaneous (upper right) and severe gap formation after thrombin stimulation (lower right). b MIR155 transfected HUVECS  (MIR155high) were 
grown under constant detection of the transendothelial resistance (TER) until confluency was reached. Challenge with thrombin showed a stronger 
decrease and slower recovery (endpoint p < 0.05) in  MIR155high compared to naïve ECs. c Continuous TER between vehicle and Anti-MIR155 
challenged with thrombin showed an amelioration of maximal response and faster re-bound recovery than the corresponding control group 
(deepest drop point p < 0.05) d Densitometry from C57BL/6J mouse lungs challenged with either LPS (17.5 mg/kg BW, n = 5) or vehicle (NaCl 
0.9%, n = 7). After 16 h they were killed and Claudin-1 (CLDN-1) and b-Actin were detected by immunoblotting (p < 0.05). e Bar graphs showing 
normalized mRNA of Claudin-1/bActin in  MIR155high and naïve (CTR) HUVECs (n = 6–7; p < 0.01). f Bar graphs showing densitometry results of 
Claudin-1/bActin immunoblots in  MIR155high versus naïve (CTR) HUVECs (n = 6–7; p < 0.01). g Bar graphs showing immunoprecipitation of the 
Claudin-onefold enrichment normalized to GAPDH (n = 4, p < 0.05), after the overexpression of MIR155 in HUVECs (n = 4, p < 0.05)
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mice were regularly scored for severity of disease by a 
single-blinded investigator using a standardized activity 
score (Additional file  1: Table  S4). Consistent with the 
permeability data,  MIR155+/− mice had a better physical 
performance indicating a less severe disease manifesta-
tion than all other groups over a 96 h observation period 
(Fig.  5a) and indeed showed a clear survival benefit by 
approximately 60% compared to the  MIR155+/+ mice. 
(Mantel–Cox Test, p < 0.05, Fig. 5b).
Translational evidence of MIR155 regulation in human 
disease
Given the discovery of both cross-species regulation and 
relevance of MIR155 in increased endothelial perme-
ability, we set out to investigate its regulation in a human 
organism. To do this, we followed two strategies. First, 
we analyzed BALf and serum from critically ill patients 
suffering from ARDS—a syndrome that is pathophysi-
ologically based on increased vascular permeability. 
Patients characteristics are summarized in Table  1. To 
our surprise, circulating MIR155 levels were not different 
between controls and ARDS patients (Fig. 6a). Given that 
we identified MIR155 with the RNA seq specifically in 
the pulmonary endothelium, we analyzed local MIR155 
abundance in the alveoli (i.e., BALf) of healthy controls 
and ARDS patients. The healthy volunteers (n = 5) had 
a median age of 26.9 years [IQR 22.5–33.1] and were all 
male. Consistent with our previous findings, we found a 
massive MIR155 upregulation in ARDS patients in this 
local compartment, close to the pulmonary endothelium 
Fig. 5 Effect of MIR155 depletion on clinical outcomes in murine sepsis. a Box and whiskers showing a descending activity score (explained in 
Additional file 1: Table S2.) that is attenuated in the heterozygote background with a significant difference at all time points calculated by Kruskal–
Wallis test (*p < 0.05, **p < 0.001). b Kaplan–Meier-survival analysis of mice suspected to cecal ligature & puncture (CLP) showing improved outcome 
in heterozygous knockout mice (p = 0.0135 with Mantel–Cox test)
Fig. 6 Translational evidence of MIR155 regulation in human disease. a Box and whisker plots showing normalized circulating MIR155 levels in 
serum of healthy controls (CTR, n = 5) and patients with acute respiratory distress syndrome (ARDS, n = 16) b Box and whisker plots showing 
normalized MIR155 in bronchoalveolar lavage fluid (BALf ) of the same patients as in a (**p < 0.001), c Box and whisker plots showing normalized 
MIR155 in immediate postmortem kidney biopsies from healthy control biopsies (CTR, n = 8) and septic acute kidney injuries (sep AKI, n = 12) 
(*p = 0.02)
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(Fig. 6b). To test MIR155 regulation in other organs fre-
quently affected during sepsis, we analyzed immediate 
post-mortem kidney biopsies from patients with septic 
acute kidney injury compared to healthy parts of tumor 
nephrectomy samples. Again, we could confirm that 
MIR155 was significantly upregulated in human septic 
kidneys (Fig.  6c). Together, these findings highlight the 
translational relevance of our results.
Discussion
Using an unbiased small RNA sequencing approach, we 
found that MIR155 was highly upregulated in the pulmo-
nary endothelium of endotoxemic mice. MIR155 overex-
pression was sufficient to induce spontaneous vascular 
leakage in zebrafish, augment pathological responses in 
cultured human endothelial cell monolayers and exac-
erbate the endothelial inflammatory response in murine 
sepsis. Moreover, pharmacological inhibition or genetic 
depletion of MIR155 prevented breakdown of the vascu-
lar barrier and improved global outcome in animal mod-
els of systemic inflammation and sepsis. Finally, MIR155 
was also detectable in diverse human samples highlight-
ing the potential translational relevance of our experi-
mental findings.
In general, the role of MIRs in endothelial response 
to systemic inflammation is not well understood. To 
our knowledge, only a single study has linked a panel 
of MIRs (including MIR155) to endothelial inflamma-
tion [18], whereas most MIR155 research has focused 
on T-cell biology [19, 20]. Three independent reports 
support our investigation of MIR155 in the inflamed 
vasculature. First, Han et al. reported increased circulat-
ing MIR155 levels in human sepsis [21]. Second, Pena-
Philippides et al. implicated MIR155 in the regulation of 
endothelial tight junctions after cerebral ischemia [22]. 
Specifically, they reported that inhibition of MIR155 for-
tified monolayers of human primary brain microvascu-
lar endothelial cells against barrier breakdown following 
oxygen–glucose deprivation. Studying lung microvas-
cular ECs, Pfeiffer, et  al., concluded that inhibition of 
MIR155 could blunt microvascular endothelial expres-
sion of inflammatory mediators [18].
Given that our transcriptomics approach in endotox-
emic mice revealed MIR155 upregulation, we first sought 
to clarify if elevated endothelial MIR155 was injurious 
or adaptive. Transparency of larval zebrafish and ease of 
gene transduction makes this model amenable to study-
ing vascular phenotypes. Overexpression of MIR155 
indeed revealed compromised vascular integrity in two 
different assays, supporting the conclusion that excess 
MIR155 may be alone be injurious and may potentiate 
adverse responses to the septic milieu. Next, we investi-
gated a B6.Cg-Mir155tm1.1Rsky/J knockout mouse to (1) 
test whether MIR155 was required for a severe inflam-
matory response; (2) evaluate the MIR155 hypothesis 
in a mammalian species; and (3) explore its relevance 
in models of human disease. Although endotoxemia is 
not a model of sepsis per se, the consequences of sterile 
cytokine storm are still of translational interest, and this 
noxious stimulus is an established trigger of pulmonary 
vascular hyperpermeability, a key phenotype of interest 
[23, 24]. LPS strain and dose were tailored in a pilot study 
to induce significant pulmonary edema early in cytokine 
storm rather than to evaluate overall survival. To study 
survival, we applied the murine gold standard sepsis 
model of CLP (that was piloted to a mortality of 75%) to 
MIR155 knockouts.
The absence of a gene-dose effect—namely that het-
erozygous mice were protected, whereas null mice were 
not—was unexpected. However, our group has observed 
similar results in the context of Angiopoietin-2, another 
regulator of endothelial permeability [25]. Several 
hypotheses are possible. First, there might be a subtle 
developmental effect of complete gene loss that is exac-
erbated by the stress of sepsis—in the case of Angiopoie-
tin-2, null mice have marked lymphedema from aberrant 
lymphangiogenesis. Second, compensatory develop-
mental and/or physiological mechanisms may become 
activated with complete gene loss. For example, compen-
satory upregulation of MIR146a could be implicated in 
MIR155 knockouts [18]. However, we did not find such 
an association with MIR155 gene dose (data not shown). 
Therefore, future experiments will be required in order to 
explore the lack of protection against sepsis exhibited by 
MIR155 knockout mice.
Different compartments (lung, kidney, serum) were 
analyzed in the human components of this study in order 
to parse local and systemic regulation of MIR155. First, 
we compared bronchoalveolar lavage (BAL) fluid and 
serum samples from patients with ARDS versus healthy 
controls. Although reported by others [26], we did not 
observe a significant change in circulating MIR155 
among ARDS patients. Yet, these very same patients 
showed clear MIR155 elevation in BAL samples. While 
this difference may be attributable to underlying patient 
and disease characteristics, the presence of a BAL-spe-
cific difference in MIR155 concentration raises the pos-
sibility of organ-specific actions of this microRNA. The 
human kidney data also suggest regional regulation 
of MIR155. However, results from these post-mortem 
specimens may be difficult to interpret as they repre-
sent the end stage of sepsis with multiple organ failure. 
On the other hand, biopsies from failing organs in sep-
sis are extremely challenging to acquire, and the biopsy 
itself could be harmful with limited potential benefit to 
the individual patient.
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Our study has important limitations. The MIR155 
knockout model was neither conditional nor organ-spe-
cific. Therefore, improvement in overall survival follow-
ing CLP may be partially attributable to non-endothelial 
effects. The observation that heterozygosity but not com-
plete gene depletion protects from endothelial injury 
requires further investigation. Finally, the underlying 
molecular mechanisms regulating MIR155 merit future 
study.
Conclusions
We found cross-species evidence in knockout mice, 
transgenic zebrafish, human endothelial cells and criti-
cally ill patients that MIR155 is upregulated in the 
endothelium during systemic inflammation. MIR155 
upregulation may lead to vascular barrier breakdown 
by targeting the tight-junction protein Claudin-1. Con-
versely inhibition of MIR155 may improve vascular 
integrity and overall survival, making this microRNA a 
putative therapeutic target for further exploration in sep-
sis and related indications. Future experimental studies 
are needed to understand the regulation of MIR155 and 
to elucidate its downstream effects in multiple cell types.
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